---
layout: post
title: "Information Requests and Discipline Review Letters Under Generic Drug User Fee Amendments; Guidance for Industry; Availability"
date: 2026-02-05 18:57:51 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-01605
original_published: 2022-01-27 00:00:00 +0000
significance: 8.00
---

# Information Requests and Discipline Review Letters Under Generic Drug User Fee Amendments; Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** January 27, 2022 00:00 UTC
**Document Number:** 2022-01605

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Information Requests and Discipline Review Letters Under GDUFA." This guidance explains how FDA will issue and use an information request (IR) and/or a discipline review letter (DRL) during the assessment of an original abbreviated new drug application (ANDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). This guidance finalizes the draft guidance of the same title issued on December 18, 2017.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/01/27/2022-01605/information-requests-and-discipline-review-letters-under-generic-drug-user-fee-amendments-guidance)
- API: https://www.federalregister.gov/api/v1/documents/2022-01605

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
